Scott David Lee (Scott Lee, Scott D Lee)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Ulcerative Colitis

Disease Activity

Top Venues

Crohn's & colitis 360

Inflammatory bowel diseases

Digestive diseases and sciences

JMIR research protocols

This page only lists publications with an associated author ORCID identifier.

Publications

Scott David Lee, Keith A Betts, Ella Xiaoyan Du, Xiaoyu Nie, Komal Gupte-Singh, Timothy Ritter
Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & colitis 360 6 (2) (2024)
Scott David Lee, Keith A Betts, Ella Xiaoyan Du, Xiaoyu Nie, Komal Gupte-Singh, Timothy Ritter
Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & colitis 360 6 (2) (2024)
Kendra J Kamp, Kindra Clark-Snustad, Linda Yoo, Samantha Hunter, Kevin Cain, Rona L Levy, Neelendu Dey, Scott David Lee, Laurie Keefer, Margaret Heitkemper
A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial. JMIR research protocols 12 (2023)
Jeffrey Jacobs, Kindra Clark-Snustad, Scott David Lee
Deep Remission in Severe Refractory Crohn's Disease With Mycophenolate Mofetil. Inflammatory bowel diseases (2022)
Scott David Lee, Kendra Kamp, Kindra Dawn Clark-Snustad
Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn's Disease. Crohn's & colitis 360 4 (2) (2022)
Laurent Peyrin-Biroulet, Subrata Ghosh, Scott David Lee, Wan-Ju Lee, Jenny Griffith, Kori Wallace, Sofie Berg, Xiaomei Liao, Julian Panes, Edward V Loftus, Edouard Louis
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Alimentary pharmacology & therapeutics (2022)
Scott David Lee, Anand Singla, Jason Harper, Mitra Barahimi, Jeffrey Jacobs, Kendra J Kamp, Kindra Dawn Clark-Snustad
Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn's Disease. Digestive diseases and sciences 67 (8) (2022)
Scott David Lee, Kendra Kamp, Kindra Dawn Clark-Snustad
Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn's Disease. Crohn's & colitis 360 4 (2) (2022)
Scott David Lee, Anand Singla, Jason Harper, Mitra Barahimi, Jeffrey Jacobs, Kendra J Kamp, Kindra Dawn Clark-Snustad
Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease. Inflammatory bowel diseases (2021)